“Global OTC Pharmaceutical market set to grow to $235bn by 2024” says new Visiongain report

31 July 2019
Pharma

Visiongain has launched a new pharma report Global OTC Pharmaceutical Market Forecast 2019-2029: Cough, Cold and Allergy, Analgesics, Gastrointestinal, Dermatology, Eye Care, Smoking Cessation Aids, Others.

There has been greater liberalisation of OTC marketing approvals and OTC switches. This is being driven by the benefits it offers to many stakeholders: increased revenue for pharma companies, reduced costs for governments, enhanced status for pharmacists and greater choice and availability for consumers. The rising cost of healthcare across the globe and the effects of the economic recession mean that the trend of favouring OTC switching is very likely to continue.

The lead analyst of the report commented "Electronic pharmacy kiosks, self-assessment and diagnostic tools, and home monitoring systems could increasingly help to support safe and effective self-medication with OTC products. These could potentially alleviate concerns by regulatory authorities regarding whether consumers would be able to decide whether OTC treatment is appropriate.

The current global trend is towards liberalisation of OTC advertisement regulation, driven by government enthusiasm for OTC products in a bid to cut healthcare costs. Many companies are trying to communicate directly with consumers through online and other media, bypassing input from medical professionals."

Leading companies featured in the report include AstraZeneca PLC, Bayer AG, Daiichi Sankyo Company, Limited, GlaxoSmithKline PLC, Johnson & Johnson, Mylan N.V., Pfizer, Inc., Proctor & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever